Home
overview
The increase in incidence in allergies, particularly in the US and Western Europe, has been phenomenal, making the market for allergy treatments big business. Over 50 million people in the US suffer from allergies and the numbers continue to increase.

SMi's 2nd annual Prevention & Treatment of Allergy Conference will evaluate the progress that has been made in understanding allergic reactions, providing the industry with an update on the current global market trends and product developments. The event aims to explore changing market dynamics, to provide companies with an evaluation of where the industry is headed and where the future opportunities lie, assessing current pipelines and future areas for research.

The Conference will discuss advances in effective allergy diagnosis, as well as reviewing developments in allergy therapeutics including food allergy/intolerance, allergic rhinitis, asthma and paediatric allergies. It will look at how to relate a therapeutic product to the consumer for effective allergy management and the commercial implications including the advantages of disadvantages of OTC status. A unique opportunity to learn from leading industry experts including:

  • Dr Badrul Chowdhury, Director, Division of Pulmonary & Allergy Drug Products, US Food & Drug Administration (FDA)
  • Dr Daniel Rotrosen, Director, Division of Allergy, Immunology & Transplantation, National Institute of Allergy & Infectious Diseases
  • Dr Ronald Rabin, Senior Staff Fellow, Office of Vaccine Regulation & Research, US Food & Drug Administration (FDA)
  • Dr Edward Philpot, Senior Director, Allergy, GlaxoSmithKline
  • Dr Heribert Staudinger, Vice President, Allergy & Respiratory Disease, Schering-Plough
  • Dr Howard Druce, Senior Director, Clinical Research & Medical Affairs, Pfizer
  • Dr Eric Meldrum, Director, Asthma Biology Department, GlaxoSmithKline
  • Dr Bertil Lindmark, Vice President & Global Medical Director, Respiratory & Inflammation Therapeutic Area, AstraZeneca
  • Prof Sten Dreborg, Professor Emeritus, Paediatric Allergy, University of Oslo

    The essential Conference on:
    • THE ALLERGY MARKET IN 2004
      Where does the market go from here?
    • ALLERGY VACCINATION
      Ground-breaking advances in the field, including vaccinations to target IgE
    • ANTI-HISTAMINES & RHINITIS
      The future for current treatments, including nasal corticosteroids
    • ALLERGIC ASTHMA
      The value of combination treatments in asthma
    • ALLERGEN-SPECIFIC IMMUNOLOGY
      Prospects for the future
  • Conference programme

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Daniel Rotrosen

    Dr Daniel Rotrosen, Director, Division of Allergy, Immunology & Transplantation, National Institute of Allergy & Infectious Diseases

    9:10 THE GLOBAL ALLERGY MARKET

    Keith Allan

    Keith Allan, Head, Global Product Advocacy, Novartis

  • Allergy market has seen dramatic growth over last 10 years
  • Mainly due to new anti-histamines and nasal steroids
  • More and more influenced by global guidelines
  • With greater OTC availability, DTC and generic competition – will the financial rewards of this market be less attractive to big pharma?
  • 9:40 NIH-SPONSORED CLINICAL RESEARCH IN ALLERGIC DISEASES

    Dr Daniel Rotrosen

    Dr Daniel Rotrosen, Director, Division of Allergy, Immunology & Transplantation, National Institute of Allergy & Infectious Diseases

  • Overview of NIAID-sponsored clinical research networks
  • Description of ongoing and planned phase I-III studies
  • Opportunities for public-private partnerships
  • 10:20 ADVANCES IN ALLERGEN SPECIFIC IMMUNOLOGY: THE NEXT FIVE YEARS

    Dr Lars Jacobsen

    Dr Lars Jacobsen, Head, Medical Communication & Clinical Relations, ALK-Abello

  • The allergic cascade and potential treatment options
  • Allergen specific antibodies and their receptors
  • Atopy and T-Helper cells
  • Inflammation and allergen specific immunology
  • 11:00 Morning Coffee

    11:20 TOLL-LIKE RECEPTORS AND ALLERGY

    Dr David Persing

    Dr David Persing, Vice President, Discovery Research, Corixa Corporation

  • Biology of toll-like receptors
  • TLR4 as a target for allergic disease
  • MPL and synthetic TLR4 agonists
  • Clinical development
  • 12:00 ANTIGEN-SPECIFIC SUPPRESSION OF ALLERGIC DISEASE

    Dr Brian Champion

    Dr Brian Champion, Vice President, Research, Lorantis

  • Effector/regulator balancing of immune responses
  • Allergic disease: T-cell subset imbalance
  • Immunity to allergens in non-allergic individuals: tolerance or immune homeostasis?
  • Modulation of immune responses by notch ligands
  • Notch ligands as novel therapeutics for allergic disease
  • 12:40 Networking Lunch

    14:00 POPULATION BIOLOGY OF ALLERGIC RESPONSES

    Dr Fiona Harding

    Dr Fiona Harding, Staff Scientist, Genencor International

  • Detection of human population-based allergic responses
  • Application to the selection and creation of hypoallergenic proteins
  • 14:40 ALLERGIC, ATOPIC AND NON-I-E-MEDIATED ALLERGIC DISEASE DEVELOPMENT

    Prof Sten Dreborg

    Prof Sten Dreborg, Professor Emeritus, Paediatric Allergy, University of Oslo

  • Definition of allergy, atopy and allergic and atopic disease
  • Maturation of the immune system during pregnancy and early life
  • The natural course of development of allergy in high risk foetuses and infants
  • Primary prevention of atopic disease in infants: is it possible
  • 15:20 THE RELATIONSHIP BETWEEN VIRAL RESPIRATORY INFECTIONS AND ASTHMA

    Dr Ronald Rabin

    Dr Ronald Rabin, , Senior Staff Fellow, Office Vaccine Regulation & Research, US Food & Drug Administration (FDA)

  • The role of respiratory viruses in the onset of allergy and atopy
  • How respiratory viral infections trigger wheezing
  • Can viral vaccines be ‘engineered’ with asthma in mind?
  • 16:00 Afternoon Tea

    16:20 THE VALUE OF COMBINATION TREATMENTS IN ASTHMA

    Dr Eric Meldrum

    Dr Eric Meldrum, Director, Asthma Biology Department, GlaxoSmithKline

  • Market impact of successful combinations
  • Clinical impact of combination approaches
  • Combination approaches for the future
  • 17:00 COMBINATION THERAPIES

    Dr Bertil Lindmark

    Dr Bertil Lindmark, Vice President & Global Medical Director, Respiratory and Inflammation Therapeutic Area, AstraZeneca

  • Currently approved products
  • Specific properties of the combinations
  • Market evolution
  • Future combinations
  • Combination patents
  • Regulatory situation
  • 17:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Matthew Moyles

    Dr Matthew Moyles, Vice President of Research, Tanox

    9:10 ALLERGY VACCINES

    Dr Alan Wheeler

    Dr Alan Wheeler, Research & Development Consultant, Allergy Therapeutics

  • History of allergy vaccination (allergen specific desensitisation)
  • Advantages and disadvatages
  • Development of different vaccine formulations
  • Mechanisms of successful therapy
  • Current thinking on mechanistic targets
  • Clinical use and benefits of adjuvants in modern products
  • 9:40 AN ALLERGY VACCINE TARGETING IGE

    Dr Lars Hellman

    Dr Lars Hellman, Chief Scientific Officer, Resistentia Pharma

  • Methods to reduce circulating IgE
  • Methods to brake self tolerance
  • Patient groups that may benefit
  • Preclinical studies - proof of concept
  • Toxicology
  • Active contra passive immunisation
  • Recent developments
  • 10:20 THE DISCOVERY AND DEVELOPMENT OF A NOVEL CLASS OF MAST CELL ACTIVATION INHIBITORS FOR ALLERGY AND ASTHMA

    Dr Donald Payan

    Dr Donald Payan, Executive Vice President & Chief Scientific Officer, Rigel Pharmaceuticals

  • Potent and selective inhibitors of mast cell activation by IgE have been identified and developed following HTS in primary human mast cells
  • Inhibiting the SYK kinase in mast cells results in a profound decrease in degranulation (histamine and tryptase release), cytokine production and release (TNFa, I16, I18), and mediators derived from arachidonic acid (PGD2, LTC4)
  • SYK inhibitors block acute and chronic allergic/inflammatory changes in animal models of asthma, collagen-induced arthritis and EAE
  • Nasally inhaled R112 showed no adverse effects and significantly diminished mediators released into the nose of allergic patients challenged by selective allergens. Clinical symptoms demonstrated improvement following a single dose of R112 in an allergen study
  • R112 and follow-on compounds are moving into clinical development for allergic and inflammatory diseases
  • 11:00 Morning Coffee

    11:20 SUBLINGUAL IMMUNOTHERAPY

    Dr Torbjørn Bjerke

    Dr Torbjørn Bjerke, Executive Vice President, Research & Development, ALK-Abello

  • Possible basic mechanisms
  • Clinical proof of concept
  • Safety profile
  • Further developments
  • 12:00 RX-TO-OTC

    Dr Badrul Chowdhury

    Dr Badrul Chowdhury, Director, Division of Pulmonary and Allergy Drug Products, US Food & Drug Administration (FDA)

  • The allergy market in 2004
  • The implications for the antihistamine treatment market
  • The implications for the nasal spray treatment market
  • Regulatory issues
  • Efficacy issues
  • Safety issues: the impact on the patient
  • 12:40 Networking Lunch

    14:00 A CASE STUDY FROM SCHERING PLOUGH

    Dr Heribert Staudinger

    Dr Heribert Staudinger, Vice President, Allergy Respiratory Disease, Schering Plough

  • Nasal polyposis:
  • Improvement in nasal congestion
  • Reduction in polyp size assessed by endoscopy
  • Improvement in nasal inspiratory flow
  • Is there a place for nasal corticosteroids in the treatment of sinusitis?
  • Treatment with antibiotics vs treatment with nasal corticosteroids in sinusitis
  • 14:40 A STUDY OF RHINITIS

    Dr Edward Philpot

    Dr Edward Philpot, Senior Director, Allergy, GlaxoSmithKline

  • Types
  • Diagnoses
  • Co-morbidities of rhinitis
  • Pharmacologic treatment: current and future
  • 15:20 Afternoon Tea

    15:40 THE FUTURE FOR ANTI-HISTAMINE TREATMENTS

    Dr Howard Druce

    Dr Howard Druce, Senior Director, Clinical Research & Medical Affairs, , Pfizer

  • First generation: the background
  • Second generation: more effective treatments?
  • Towards the third generation?
  • The potency argument: is stronger superior?
  • CNS safety of anti-histamines and performance impairment
  • 16:20 A CASE STUDY FROM UCB PHARMA

    Dr Serge Kouzan

    Dr Serge Kouzan, Head, Development Therapeutic Group, Allergy, Respiratory Disease, UCB Pharma

  • The ARIA guidelines: persistent rhinitis
  • Long term Quality of Life trials
  • Anti-histamine and disease co-morbidity
  • New rhinitis surrogate markers
  • Anti-histamine and immunity
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.